As investments and collaborations hit a record high, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases, exciting efforts have now turned to a wide range of other diseases, from CNS, oncology, metabolism and more. Despite the growing momentum, much needs to be addressed in terms of targeted delivery, safety, and efficiency to fully unleash the therapeutic value of RNAi drugs.
Built with large pharma and pioneering biotech insights, the RNAi- Based Therapeutics Summit unites key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape, extrahepatic delivery, & PKPD for CNS, oncology & beyond.
With a number of RNAi based clinical candidates emerging and excitement building in the field, join the RNAi Based Therapeutic Summit – the comprehensive industry guide for senior biopharmaceutical leaders from discovery, translation & clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need.
2021 Speaker Faculty Included:
Vice President, Research Informatics
Professor & Chair of Pharmacology and Toxicology Technical
University of Munich
Senior Scientist Khvorova Lab
University of Massachusetts Medical School